Ori Biotech

🤝 We’ve launched our Preferred Partner Network (PPN) to ensure the next generation of CGTs can realize their full clinical and commercial potential. Our PPN brings together top academic medical centers and contract development and manufacturing organizations to deliver best-in-class solutions to accelerate the development and commercialization of cell and gene therapies. PPN members gain preferred access to our innovations – including IRO® – which has demonstrated the ability to increase throughput, reduce costs of goods, and accelerate development timelines. Founding members in the U.S. include Charles River Laboratories, CTMC - a joint venture between Resilience + MD Anderson Cancer Center, ElevateBio, Kincell Bio and other currently undisclosed partners. PPN members will become Centers of Excellence for the IRO® platform, combining best-in-class technology with industry-leading development and manufacturing capabilities. This partnership approach helps ensure that along with our partners we remain at the cutting edge of cell therapy manufacturing innovation, offering access to proven, best-in-class solutions to meet the evolving needs of our shared customers. Read our press release: https://lnkd.in/edCMkQbE Schedule a hands on demo to see how IRO® could help you scale the impact of your therapies: https://lnkd.in/eXEXEGZZ #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact 

🧬 Behind every CAR-T breakthrough is a team of dedicated researchers, clinicians, and coordinators working tirelessly to bring new treatments to patients. At Penn Medicine, University of Pennsylvania Health System, clinical research nurse Joanne Shea, project manager Reenie Martins, and trial sample coordinator Rutendo Manyeka, MS are among the many experts ensuring CAR-T trials run smoothly – from patient care to data collection. Their work, alongside Dr. Carl June, Dr. Bruce Levine, and Dr. David Porter, has helped take CAR-T from early trials to FDA-approved therapies. Without teams like these, the groundbreaking science behind CAR-T would not be transformed into life-transforming treatments. As CAR-T progresses, their work is redefining how these therapies are developed and delivered – adapting protocols, refining techniques, and ensuring treatments reach the patients who need them most. Their dedication is what turns research into reality for people fighting cancer, and motivates us in our mission to enable widespread patient access. Thank you Penn Medicine for sharing insights into the hard-working team delivering CAR-T therapy to patients: https://lnkd.in/eUWJ4Yxb #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

🔬 IRO® optimizes transduction efficiency, so you no longer have to sacrifice biological performance for automation. Transduction efficiency is a key driver of CAR-T therapy success. With its proprietary transduction mixing protocol, IRO improves virus-cell and cell-cell interactions, enabling more effective gene transfer at lower MOIs. Our data shows: 📈 Figure A: Transduction efficiency at different MOIs. IRO outperformed the control at each concentration of viral vector. 📈 Figure B: Total CAR+ cell yield in IRO and control on Day 8. Dotted lines show a 40-75% increase in total CAR-T cells using IRO compared to the control, while using 50% less viral vector. 💫 CAR-T yield in IRO using MOI of 0.25 produced a similar yield to cells grown in control using MOI of 1.0. By optimizing transduction and cell growth, IRO can reduce the amount of virus required and shorten the time it takes to achieve target CAR-T yields, ultimately reducing the cost of goods – helping to scale effectively while maintaining high product quality. Contact the Ori team to learn how IRO can help you improve transduction efficiency and scale your impact: https://lnkd.in/d9GvsPf #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

🔬 Cell processing is one of the biggest bottlenecks in CGT manufacturing In the second part of Jason C. Foster’s interview with BioPharm International, he explores how tech transfer – transitioning from early-stage development to full-scale production – can be a major hurdle, adding time and complexity to the already lengthy manufacturing process. IRO® – the new standard in CGT manufacturing helps to resolve these roadblocks. Cutting the cell expansion phase by nearly half and enabling parallel processing for multiple patients, IRO accelerates product development while maintaining exceptional biological performance.  Scaling the manufacturing and deployment of cell therapies will help ensure they are not only approvable but accessible and affordable too. Read more: https://lnkd.in/etVeYWnn #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

Our team is hitting the road for two key events this month! Here’s where you can find us ⬇️     🔹 Terrapinn's Advanced Therapies Congress  📍 ExCel, London  📆 March 18 – 19  👥 Elena Chikunova & Diaa Razza are attending Advanced Therapies is Europe’s largest commercial CGT gathering, bringing industry leaders and start-ups with insights from across the CGT value chain. Register: https://lnkd.in/gBZjdrk 🔹 Boston Society Gene and Cell Therapy Conference  📍 Bristol-Myers Squibb, Cambridge, MA  📆 March 20 – 21  👥 John Oh attending Boston Society Conference is a leading CGT forum uniting industry leaders, researchers, and regulators to explore breakthroughs, regulatory challenges, and the future of CGT. Register: https://lnkd.in/euDJw-ZN Connect with Elena, Diaa and John to learn more about how IRO® can help to scale the impact of these incredible therapies. #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

“The cancer kept coming back stronger and faster, and I was running out of options, but CAR-T therapy gave me a second chance.” – Rijesh Nair. Diagnosed with diffuse large B-cell lymphoma in 2023, Rijesh underwent chemotherapy and radiation, but his cancer kept coming back – spreading to his brain and spinal cord. With standard treatments proving unsuccessful at fighting his cancer, Kokilaben Dhirubhai Ambani Hospital offered Rijesh CAR-T cell therapy. In late 2024, Rijesh received CAR-T therapy, and now, he’s in remission. As the industry continues to make incredible scientific progress within CAR-T, thinking about manufacturing early in development is critical to enabling widespread patient access to these therapies. Thank you Kokilaben Hospital for sharing Rijesh’s journey ➡️ https://lnkd.in/dHgZZ-fj  #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology  

🦾 IRO® delivers significant reduction in cell therapy manufacturing cost of goods (COGs) Reducing COGs in manufacturing is critical to ensuring these life-saving therapies can be produced at scale to meet growing patient demand. 📉 Optimizing transduction efficiency using IRO can reduce the lentiviral vector requirement and time required to achieve target CAR-T yield. 💫 When considering these advantages, along with the full suite of benefits that the automated IRO platform provides – including less clean room time and fewer manual steps – Ori expects IRO to deliver a 30-50% reduction in COGs. 💰In a cost model analysis that assumes use of MOI of 0.5 for transduction, calculated COG per dose is $94k with IRO – a saving of 40% on the current industry standard of $156k. By delivering superior biological performance vs control alongside the benefits of automation, IRO reduces process times and is expected to deliver meaningful reduction in COGs – helping to scale the impact of these therapies and enable more widespread patient access. Contact the Ori Team to learn how IRO can help reduce COGs and scale your impact: https://lnkd.in/d9GvsPf #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

🔬 Commercial-scale manufacturing remains one of the biggest challenges in cell and gene therapy. In the first of a two-part interview with BioPharm International, our CEO Jason C. Foster discussed how our IRO® platform is addressing this bottleneck – delivering higher throughput, reducing manufacturing costs, and enhancing product quality and consistency. Unlike traditional therapies, cell therapies are living medicines that require highly specialized manufacturing. Existing processes are manual, expensive, and prone to variability. By automating essential steps in the manufacturing pathway, IRO brings consistency and efficiency to cell therapy production – scaling the impact of these therapies and enabling widespread patient access. With the first IRO platforms already deployed, we’re working with partners to ensure that next-generation therapies are able to meet patient demand.  Read more: https://lnkd.in/e-dkG69n #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology 

Interested to see how IRO® could work for you? At our Boston event last year, our commercial and technical team conducted live demos of IRO, showcasing how our platform delivers exceptional biological performance alongside the benefits of automation so you can maximize your clinical and commercial impact. With live demos running throughout the evening, our partners got to experience the new standard of cell and gene manufacturing. Watch the demo ⬇️ If you’d like to learn more about deploying IRO to help you scale the impact of your therapies, reach out to our Business Development team Kale Feeter, Sarah Haecker, PhD, Marianna Mavropoulou, or John Oh to schedule a meeting. #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

Meet us at Engineering Conferences International (ECI), Malta next week! Ori Bioprocess Scientist Gergana Atanasova will be presenting research on “Flexible mixing strategies for CAR-T manufacturing in the bellows bioreactor” at the Single-Use Technologies VII: Revolutionizing Manufacturing for Tomorrow’s Medicines event. 📆 Thursday, March 20 ⏰ 8:30-9:00 am CET 📍‘Future Perspectives and Emerging Trends’ session, Portomaso Suite II & III The 4-day conference will bring together speakers and attendees from industry and academia, to advance knowledge in the fundamental science and engineering underpinning Single-Use Technology. Register ➡️ https://lnkd.in/euXhEwsu  #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact